A Non-interventional Study Investigating Semaglutide in Combination With Lifestyle-based Modifications for the Management of Obesity in Real-World Clinical Practice in Germany (WeGo Real Germany).

NCT07081178 · Terminated

Last updated 2026-05-28

This study is observing how the medication semaglutide, combined with lifestyle changes, affects weight in adults with obesity in real-world clinical settings in Germany.

Status Terminated Stopped early and will not restart.

Type Observational

Participants 100 people

Who can join Ages 18+ · all sexes

Timeline Started 2025-08 · est. completion 2025-12

Where 1 site · Germany

What this study is testing ClinicalTrials.gov NCT07081178 ↗

Description as written by the study sponsor.

Participants will be treated with commercially available semaglutide according to routine clinical practice at the discretion of the treating physician for the management of obesity. The purpose of this study is to collect data on the effect of Semaglutide under everyday conditions in participants. Participants and doctor had already decided that they will get semaglutide prescribed by doctor, independently of patient's participation in this study. The study will last for 12 months.

Treatments tested

Semaglutide Drug

Semaglutide injection will be self-administered once weekly subcutaneously at any time of the day with or without meals.

Main thing measured	Change in relative body weight
Sponsor	Novo Nordisk A/S
Conditions studied	Obesity
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07081178 ↗